CASI Pharmaceuticals' short interest declined 9.4% in September, with 146,500 shares shorted.
CASI Pharmaceuticals saw a 9.4% decline in short interest in September, with 146,500 shares shorted, down from 161,700 on September 15. This represents 3.4% of the company’s shares, with a days-to-cover ratio of 4.3 days. The company reported a quarterly loss of $0.52 EPS, surpassing estimates. CASI focuses on developing therapeutics, including EVOMELA for treating multiple myeloma.
October 17, 2024
3 Articles